ADGRG6 (Adhesion G Protein-Coupled Receptor G6), also known as GPR126. is a member of the adhesion GPCR family, which plays critical roles in cell signaling, adhesion, and tissue development. This receptor is characterized by a large extracellular N-terminal region involved in ligand binding and cell-cell interactions, coupled with a seven-transmembrane domain typical of GPCRs. ADGRG6 is essential for Schwann cell myelination in the peripheral nervous system and cartilage development during embryogenesis. Dysregulation of ADGRG6 has been implicated in various pathologies, including neurodevelopmental disorders, skeletal defects, and cancers such as breast cancer and glioblastoma.
Antibodies targeting ADGRG6 are crucial tools for studying its expression, localization, and functional mechanisms. They enable researchers to detect ADGRG6 in tissues or cell lines via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Additionally, these antibodies facilitate investigations into receptor activation, downstream signaling pathways (e.g., cAMP and MAPK), and interactions with extracellular ligands or intracellular partners. Some studies also explore ADGRG6's potential as a therapeutic target, particularly in cancer and regenerative medicine. Both monoclonal and polyclonal antibodies are available, with validation often including knockout controls to ensure specificity. Ongoing research aims to clarify ADGRG6's diverse roles in health and disease, underscoring the importance of reliable antibody reagents in advancing this field.